Emerging lipid lowering agents targeting LDL cholesterol

References

• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. 2019 Mar 5;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the american college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;2018(Nov):8.
   Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;2019:31.
   Google Scholar
• Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015 Apr 11;385(9976):1397–1405.
   PubMed Web of Science ®Google Scholar
• Khan SU, Khan MU, Valavoor S, et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials. Eur J Prev Cardiol. 2019;2:2047487319871733.
   Google Scholar
• Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-c lowering: a systematic review and meta-analysis. JAMA. 2018 Apr 17;319(15):1566–1579.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016 Dec 13;316(22):2373–2384.
   PubMed Web of Science ®Google Scholar
• Colantonio LD, Rosenson RS, Deng L, et al. Adherence to statin therapy among us adults between 2007 and 2014. J Am Heart Assoc. 2019 Jan 8;8(1):e010376.
   PubMed Web of Science ®Google Scholar
• Presta V, Figliuzzi I, Miceli F, et al. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: analysis of a large real practice database in Italy. Atherosclerosis. 2019;285:40–48.
   PubMed Web of Science ®Google Scholar
• Kato ET, Cannon CP, Blazing MA, et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial). J Am Heart Assoc. 2017 Nov 18;6(11):e006901.
   Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018 Nov 29;379(22):2097–2107.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay D, Qureshi A, Ghosh S, et al. Safety and efficacy of extremely low ldl-cholesterol levels and its prospects in hyperlipidemia management. J Lipids. 2018;2018:8598054.
   PubMed Web of Science ®Google Scholar
• Mahmood T, Shapiro MD. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology. Curr Opin Cardiol. 2019 Sep;34(5):519–525.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Tsimikas S. Lipid-Lowering Agents. Circ Res. 2019 Feb;124(3):386–404.
   PubMed Web of Science ®Google Scholar
• Ray KK, Corral P, Morales E, et al. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019 Aug 24;394(10199):697–708.
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Perrot N, Puri R. Therapeutic agents targeting cardiometabolic risk for preventing and treating atherosclerotic cardiovascular diseases. Clin Pharmacol Ther. 2018 Aug;104(2):257–268.
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Yamashita S, Greco MF, et al. Recent advances in synthetic pharmacotherapies for dyslipidaemias. Eur J Prev Cardiol. 2019;6:2047487319845314.
   Google Scholar
• Feng X, Zhang L, Xu S, et al. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review. Prog Lipid Res. 2019;6:101006.
   Google Scholar
• Burke AC, Huff MW. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. Curr Opin Lipidol. 2017 Apr;28(2):193–200.
   PubMed Web of Science ®Google Scholar
• Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019 Feb;30(1):1–9.
   PubMed Web of Science ®Google Scholar
• Bilen O, Ballantyne CM. Bempedoic acid (ETC-1002): an Investigational Inhibitor of ATP citrate lyase. Curr Atheroscler Rep. 2016 Oct;18(10):61.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov;28(7):13457.
   Google Scholar
• Ference BA, Ray KK, Catapano AL, et al. Mendelian randomization study of acly and cardiovascular disease. N Engl J Med. 2019 Mar 14;380(11):1033–1042.
   PubMed Web of Science ®Google Scholar
• Al Rifai M, Jia X, Al-Mallah MH, et al. Major randomized clinical trials in cardiovascular disease prevention presented at the 2019 American college of cardiology annual scientific session. Curr Atheroscler Rep. 2019 May 24;21(8):31.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2019;29:2047487319864671.
   Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019 Mar 14;380(11):1022–1032.
   PubMed Web of Science ®Google Scholar
• Samsoondar JP, Burke AC, Sutherland BG, et al. Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in ldlr(-/-) mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid. Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):647–656.
   PubMed Web of Science ®Google Scholar
• Burke AC, Telford DE, Sutherland BG, et al. Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR(±) and LDLR(-/-)) Yucatan Miniature Pigs. Arterioscler Thromb Vasc Biol. 2018 May;38(5):1178–1190.
   PubMed Web of Science ®Google Scholar
• Stoekenbroek RM, Kallend D, Wijngaard PL, et al. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol. 2018 Nov;14(6):433–442.
   PubMed Web of Science ®Google Scholar
• Khvorova A. Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. N Engl J Med. 2017 Jan 5;376(1):4–7.
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, White S, Borodovsky A, et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med. 2017 Jan 5;376(1):41–51.
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014 Jan 4;383(9911):60–68.
   PubMed Web of Science ®Google Scholar
• Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019 Sep; 4(11):1067–1075.
   PubMed Web of Science ®Google Scholar
• Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc. 2020 Jan; 95(1):77–89.
   Web of Science ®Google Scholar
• Leiter LA, Teoh H, Kallend D, et al. Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care. 2019 Jan;42(1):173–176.
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017 Apr 13;376(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins. Circulation. 2018 Sep 25;138(13):1304–1316.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Wang S. comparative effectiveness of inclisiran 100, 300, and 500 mg in a population with hyperlipidemia: a network meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2018 Aug;18(4):271–282.
   PubMed Web of Science ®Google Scholar
• Bisgaier CL, Essenburg AD, Barnett BC, et al. A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res. 1998 Jan;39(1):17–30.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Stender S, Hobbs HH. APOC3, coronary disease, and complexities of Mendelian randomization. Cell Metab. 2014 Sep 2;20(3):387–389.
   PubMed Web of Science ®Google Scholar
• Srivastava RAK, Cornicelli JA, Markham B, et al. Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-delta-mediated transcriptional mechanism. Mol Cell Biochem. 2018 Dec;449(1–2):167–183.
   PubMed Web of Science ®Google Scholar
• Oniciu DC, Hashiguchi T, Shibazaki Y, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM model of NASH. PLoS One. 2018;13(5):e0194568.
   PubMed Web of Science ®Google Scholar
• Srivastava RAK, Cornicelli JA, Markham B, et al. Gemcabene, a first-in-class hypolipidemic small molecule in clinical development, attenuates osteoarthritis and pain in animal models of arthritis and pain. Front Pharmacol. 2018;9:471.
   PubMed Web of Science ®Google Scholar
• Milonas D, Tziomalos K. Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia - spotlight on volanesorsen. Expert Opin Investig Drugs. 2019 Apr;28(4):389–394.
   PubMed Web of Science ®Google Scholar
• Stein E, Bays H, Koren M, et al. Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. J Clin Lipidol. 2016 Sep-Oct;10(5):1212–1222.
   PubMed Web of Science ®Google Scholar
• Bays HE, McKenney JM, Dujovne CA, et al. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol. 2003 Sep 1;92(5):538–543.
   PubMed Web of Science ®Google Scholar
• Mandema JW, Hermann D, Wang W, et al. Model-based development of gemcabene, a new lipid-altering agent. Aaps J. 2005 Oct 7;7(3):E513–22.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014 May 14;311(18):1870–1882.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Durst R, Lepor N, et al. Usefulness of gemcabene in homozygous familial hypercholesterolemia (from COBALT-1). Am J Cardiol. 2019 Dec 15;124(12):1876–1880.
   PubMed Web of Science ®Google Scholar
• Minicocci I, Santini S, Cantisani V, et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res. 2013 Dec;54(12):3481–3490.
   PubMed Web of Science ®Google Scholar
• Tarugi P, Bertolini S, Calandra S. Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia. J Biomed Res. 2019 Apr 22;33(2):73–81.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017 Jul 20;377(3):211–221.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019 Aug 6;140(6):470–486.
   PubMed Web of Science ®Google Scholar
• Banerjee P, Chan KC, Tarabocchia M, et al. Functional analysis of ldlr (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity. Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2248–2260.
   PubMed Web of Science ®Google Scholar
• Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017 Jul 20;377(3):222–232.
   PubMed Web of Science ®Google Scholar
• Lang W, Frishman WH. Angiopoietin-like 3 protein inhibition: a new frontier in lipid-lowering treatment. Cardiol Rev. 2019 Jul/Aug;27(4): 211–217.
   PubMed Web of Science ®Google Scholar
• Wong ND, Toth PP, Amsterdam EA, et al. Most important advances in preventive cardiology during this past decade: viewpoint from the American society for preventive cardiology. Trends Cardiovasc Med. 2019 Dec 6. pii: S1050-1738(19)30163-X.
   Web of Science ®Google Scholar
• Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019 Jul;18(7):611–621.
   PubMed Web of Science ®Google Scholar
• Karagiannis AD, Liu M, Toth PP, et al. Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation. Curr Atheroscler Rep. 2018 Mar 10;20(4):20.
   PubMed Web of Science ®Google Scholar
• Tsouka AN, Tellis CC, Tselepis AD. Pharmacology of PCSK9 inhibitors: current status and future perspectives. Curr Pharm Des. 2018;24(31):3622–3633.
   PubMed Web of Science ®Google Scholar